Andreas Handel

Andreas Handel

Auto-generated profile, based on publicly available information

Andreas Handel

Affiliations Department of Epidemiology and Biostatistics, University of Georgia, Athens, Georgia, United States of America, Center for the Ecology of Infectious Diseases, University of Georgia, Athens, Georgia, United States of America

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
YSYe Shen
Ye Shen
CLChangwei Li
Changwei Li
HDHongjun Dong
Hongjun Dong
ZWZhen Wang
Zhen Wang
LMLeonardo Martinez
Leonardo Martinez
GXGuozhang Xu
Guozhang Xu
Human infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in Wuhan city of Hubei province in China.1,2 The World Health Organization declared the coronavirus disease 2019 (COVID-19) outbreak a public health emergency of international concern on January 30, 2020. The ongoing epidemic has since affected more than 150 countries and territories. As of August 5, 2020, more than 18 million cases have been confirmed and more than 650 000 people have died.3

1 January 2011 in BMC Public Health
Verified
Journal Article
Open access
CBCatherine Aa Beauchemin
Catherine Aa Beauchemin
AHAndreas Handel
Andreas Handel
Most mathematical models used to study the dynamics of influenza A have thus far focused on the between-host population level, with the aim to inform public health decisions regarding issues such as drug and social distancing intervention strategies, antiviral stockpiling or vaccine distribution. Here, we investigate mathematical modeling of influenza infection spread at a different scale; namely that occurring within an individual host or a cell culture. We review the models that have been developed in the last decades and discuss their contributions to our understanding of the dynamics of influenza infections. We review kinetic parameters (e.g., viral clearance rate, lifespan of infected cells) and values obtained through fitting mathematical models, and contrast them with values obtained directly from experiments. We explore the symbiotic role of mathematical models and experimental assays in improving our quantitative understanding of influenza infection dynamics. We also discuss the challenges in developing better, more comprehensive models for the course of influenza infections within a host or cell culture. Finally, we explain the contributions of such modeling efforts to important public health issues, and suggest future modeling studies that can help to address additional questions relevant to public health.

3 May 2017 in Nature
Verified
Journal Article
Closed access
PDF file
JOJoshua D. Ooi
Joshua D. Ooi
JPJan Petersen
Jan Petersen
YTYu H. Tan
Yu H. Tan
MHMegan Huynh
Megan Huynh
ZWZoe J. Willett
Zoe J. Willett
AKA. Richard Kitching
A. Richard Kitching

1 August 2012 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
MJMark Jackwood
Mark Jackwood
DHDavid Hall
David Hall
AHAndreas Handel
Andreas Handel

1 November 2016 in The Lancet Global Health
Verified
Journal Article
Open access
RHRein M G J Houben
Rein M G J Houben
NMNicolas A Menzies
Nicolas A Menzies
TSTom Sumner
Tom Sumner
GHGrace H Huynh
Grace H Huynh
NANimalan Arinaminpathy
Nimalan Arinaminpathy
Richard G WhiteRichard G White
Richard G White
The post-2015 End TB Strategy proposes targets of 50% reduction in tuberculosis incidence and 75% reduction in mortality from tuberculosis by 2025. We aimed to assess whether these targets are feasible in three high-burden countries with contrasting epidemiology and previous programmatic achievements. 11 independently developed mathematical models of tuberculosis transmission projected the epidemiological impact of currently available tuberculosis interventions for prevention, diagnosis, and treatment in China, India, and South Africa. Models were calibrated with data on tuberculosis incidence and mortality in 2012. Representatives from national tuberculosis programmes and the advocacy community provided distinct country-specific intervention scenarios, which included screening for symptoms, active case finding, and preventive therapy. Aggressive scale-up of any single intervention scenario could not achieve the post-2015 End TB Strategy targets in any country. However, the models projected that, in the South Africa national tuberculosis programme scenario, a combination of continuous isoniazid preventive therapy for individuals on antiretroviral therapy, expanded facility-based screening for symptoms of tuberculosis at health centres, and improved tuberculosis care could achieve a 55% reduction in incidence (range 31-62%) and a 72% reduction in mortality (range 64-82%) compared with 2015 levels. For India, and particularly for China, full scale-up of all interventions in tuberculosis-programme performance fell short of the 2025 targets, despite preventing a cumulative 3·4 million cases. The advocacy scenarios illustrated the high impact of detecting and treating latent tuberculosis. Major reductions in tuberculosis burden seem possible with current interventions. However, additional interventions, adapted to country-specific tuberculosis epidemiology and health systems, are needed to reach the post-2015 End TB Strategy targets at country level. Bill and Melinda Gates Foundation.

4 April 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
RDRishi Desai
Rishi Desai
CHChristal D. Hembree
Christal D. Hembree
AHAndreas Handel
Andreas Handel
JMJonathan E. Matthews
Jonathan E. Matthews
BDBenjamin W. Dickey
Benjamin W. Dickey
BLBenjamin Lopman
Benjamin Lopman
Background. Noroviruses (NoVs) are the most common cause of epidemic gastroenteritis; however, the relative impacts of individual factors underlying severe illness are poorly understood. This report reviews published NoV outbreak reports to quantify hospitalization and mortality rates and assess their relationship with outbreak setting, transmission route, and strain. Methods. Using a string of terms related to “norovirus” and “outbreak,” we 2435 nonduplicate articles identified in PubMed, EMBASE, and Web of Knowledge published between January 1993 and June 2011. Inclusion criteria included outbreaks with a minimum of 2 ill persons with a common exposure and at least 1 reverse-transcription polymerase chain reaction–confirmed case of NoV disease. Univariate analyses were performed, and multivariable models were fitted to estimate the independent effect of each factor. Results. We analyzed 843 NoV outbreaks reported in 233 published articles from 45 countries. Based upon 71 724 illnesses, 501 hospitalizations, and 45 deaths, overall hospitalization and mortality rates were 0.54% and 0.06%, respectively. In multivariate analysis, genogroup 2 genotype 4 (GII.4) NoV strains were associated with higher hospitalization (incidence rate ratio [IRR], 9.4; 95% confidence interval [CI], 6.1–14.4; P < .001) and mortality rates (IRR, 3.1; 95% CI, 1.3–7.6; P = .01). Deaths were much more likely to occur in outbreaks occurring in healthcare facilities (IRR, 60; 95% CI, 6–109; P = .01). Conclusions. Our review suggests that hospitalizations and deaths were more likely in outbreaks associated with GII.4 viruses, independent of other factors, and underscores the importance of developing vaccines against GII.4 viruses to prevent severe disease outcomes.